The practical use of tumor marker determination in blader washing specimens. Assessing the urothelium of patients with superficial bladder cancer

Eduardo Orihuela, S. Vardachay, H. W. Herr, M. R. Melamed, W. F. Whitmore

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bladder washing specimens from 81 patients with recurrent multifocal superficial bladder cancer were eveluated for DNA profile by flow cytometry and cell-surface group (ABH) antigen reactivity by a modified specific erythrocyte adherence test. The study was conducted in a prospective, blind, nonrandomized fashion. Fifteen patients were treated with transurethral resection (TUR) alone and 66 with TUR and intravesical administration of bacillus Calmette-Guerin weekly for 6 weeks (TUR + BCG). Among the patients treated with TUR only, there was a notably greater rate of tumor recurrence and progression in patients with unfavorable tumor markers (aneuploidy and ABH-negative reactivity) than in those with favorable markers (diploidy and ABH-positive reactivity). The difference was less striking in patients treated with BCG, which reduced the frequency of recurrence or progression at 30 months from 87% to 44% and from 60% to 23%, respectively. This favorable effect of BCG was virtually confined to patients with initially favorable markers and to those whose initially unfavorable markers became favorable during BCG administration. Aneuploidy and negative ABH are phenotypic expressions of undifferentiation that can forecast the potential of the urothelium to form new tumors and predict invasion. To an extent, these markers are independent of the grade and stage of the disease. BCG can induce prognostically favorable conversion of the markers expression. Lack of such conversion indicates lack of response to BCG and should be regarded as evidence of persistent disease even if conventional methods do not reveal it. Therefore, sequential determination of markers is useful in monitoring patients with superficial bladder cancer treated with intravesical BCG.

Original languageEnglish (US)
Pages (from-to)1009-1016
Number of pages8
JournalCancer
Volume60
Issue number5
StatePublished - 1987
Externally publishedYes

Fingerprint

Urothelium
Tumor Biomarkers
Mycobacterium bovis
Urinary Bladder Neoplasms
Aneuploidy
Intravesical Administration
Recurrence
Physiologic Monitoring
Diploidy
Neoplasms
Flow Cytometry
Urinary Bladder
Erythrocytes
Antigens
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Orihuela, E., Vardachay, S., Herr, H. W., Melamed, M. R., & Whitmore, W. F. (1987). The practical use of tumor marker determination in blader washing specimens. Assessing the urothelium of patients with superficial bladder cancer. Cancer, 60(5), 1009-1016.

The practical use of tumor marker determination in blader washing specimens. Assessing the urothelium of patients with superficial bladder cancer. / Orihuela, Eduardo; Vardachay, S.; Herr, H. W.; Melamed, M. R.; Whitmore, W. F.

In: Cancer, Vol. 60, No. 5, 1987, p. 1009-1016.

Research output: Contribution to journalArticle

Orihuela, E, Vardachay, S, Herr, HW, Melamed, MR & Whitmore, WF 1987, 'The practical use of tumor marker determination in blader washing specimens. Assessing the urothelium of patients with superficial bladder cancer', Cancer, vol. 60, no. 5, pp. 1009-1016.
Orihuela, Eduardo ; Vardachay, S. ; Herr, H. W. ; Melamed, M. R. ; Whitmore, W. F. / The practical use of tumor marker determination in blader washing specimens. Assessing the urothelium of patients with superficial bladder cancer. In: Cancer. 1987 ; Vol. 60, No. 5. pp. 1009-1016.
@article{0bf1b9ee69834586987e200f113b2170,
title = "The practical use of tumor marker determination in blader washing specimens. Assessing the urothelium of patients with superficial bladder cancer",
abstract = "Bladder washing specimens from 81 patients with recurrent multifocal superficial bladder cancer were eveluated for DNA profile by flow cytometry and cell-surface group (ABH) antigen reactivity by a modified specific erythrocyte adherence test. The study was conducted in a prospective, blind, nonrandomized fashion. Fifteen patients were treated with transurethral resection (TUR) alone and 66 with TUR and intravesical administration of bacillus Calmette-Guerin weekly for 6 weeks (TUR + BCG). Among the patients treated with TUR only, there was a notably greater rate of tumor recurrence and progression in patients with unfavorable tumor markers (aneuploidy and ABH-negative reactivity) than in those with favorable markers (diploidy and ABH-positive reactivity). The difference was less striking in patients treated with BCG, which reduced the frequency of recurrence or progression at 30 months from 87{\%} to 44{\%} and from 60{\%} to 23{\%}, respectively. This favorable effect of BCG was virtually confined to patients with initially favorable markers and to those whose initially unfavorable markers became favorable during BCG administration. Aneuploidy and negative ABH are phenotypic expressions of undifferentiation that can forecast the potential of the urothelium to form new tumors and predict invasion. To an extent, these markers are independent of the grade and stage of the disease. BCG can induce prognostically favorable conversion of the markers expression. Lack of such conversion indicates lack of response to BCG and should be regarded as evidence of persistent disease even if conventional methods do not reveal it. Therefore, sequential determination of markers is useful in monitoring patients with superficial bladder cancer treated with intravesical BCG.",
author = "Eduardo Orihuela and S. Vardachay and Herr, {H. W.} and Melamed, {M. R.} and Whitmore, {W. F.}",
year = "1987",
language = "English (US)",
volume = "60",
pages = "1009--1016",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - The practical use of tumor marker determination in blader washing specimens. Assessing the urothelium of patients with superficial bladder cancer

AU - Orihuela, Eduardo

AU - Vardachay, S.

AU - Herr, H. W.

AU - Melamed, M. R.

AU - Whitmore, W. F.

PY - 1987

Y1 - 1987

N2 - Bladder washing specimens from 81 patients with recurrent multifocal superficial bladder cancer were eveluated for DNA profile by flow cytometry and cell-surface group (ABH) antigen reactivity by a modified specific erythrocyte adherence test. The study was conducted in a prospective, blind, nonrandomized fashion. Fifteen patients were treated with transurethral resection (TUR) alone and 66 with TUR and intravesical administration of bacillus Calmette-Guerin weekly for 6 weeks (TUR + BCG). Among the patients treated with TUR only, there was a notably greater rate of tumor recurrence and progression in patients with unfavorable tumor markers (aneuploidy and ABH-negative reactivity) than in those with favorable markers (diploidy and ABH-positive reactivity). The difference was less striking in patients treated with BCG, which reduced the frequency of recurrence or progression at 30 months from 87% to 44% and from 60% to 23%, respectively. This favorable effect of BCG was virtually confined to patients with initially favorable markers and to those whose initially unfavorable markers became favorable during BCG administration. Aneuploidy and negative ABH are phenotypic expressions of undifferentiation that can forecast the potential of the urothelium to form new tumors and predict invasion. To an extent, these markers are independent of the grade and stage of the disease. BCG can induce prognostically favorable conversion of the markers expression. Lack of such conversion indicates lack of response to BCG and should be regarded as evidence of persistent disease even if conventional methods do not reveal it. Therefore, sequential determination of markers is useful in monitoring patients with superficial bladder cancer treated with intravesical BCG.

AB - Bladder washing specimens from 81 patients with recurrent multifocal superficial bladder cancer were eveluated for DNA profile by flow cytometry and cell-surface group (ABH) antigen reactivity by a modified specific erythrocyte adherence test. The study was conducted in a prospective, blind, nonrandomized fashion. Fifteen patients were treated with transurethral resection (TUR) alone and 66 with TUR and intravesical administration of bacillus Calmette-Guerin weekly for 6 weeks (TUR + BCG). Among the patients treated with TUR only, there was a notably greater rate of tumor recurrence and progression in patients with unfavorable tumor markers (aneuploidy and ABH-negative reactivity) than in those with favorable markers (diploidy and ABH-positive reactivity). The difference was less striking in patients treated with BCG, which reduced the frequency of recurrence or progression at 30 months from 87% to 44% and from 60% to 23%, respectively. This favorable effect of BCG was virtually confined to patients with initially favorable markers and to those whose initially unfavorable markers became favorable during BCG administration. Aneuploidy and negative ABH are phenotypic expressions of undifferentiation that can forecast the potential of the urothelium to form new tumors and predict invasion. To an extent, these markers are independent of the grade and stage of the disease. BCG can induce prognostically favorable conversion of the markers expression. Lack of such conversion indicates lack of response to BCG and should be regarded as evidence of persistent disease even if conventional methods do not reveal it. Therefore, sequential determination of markers is useful in monitoring patients with superficial bladder cancer treated with intravesical BCG.

UR - http://www.scopus.com/inward/record.url?scp=0023639240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023639240&partnerID=8YFLogxK

M3 - Article

C2 - 3607723

AN - SCOPUS:0023639240

VL - 60

SP - 1009

EP - 1016

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -